Korro Bio is trading at $13.05, down 21.48%, after its earnings report disclosed Novo Nordisk’s notice to terminate the collaboration. - The November 5 release reported zero collaboration revenue, versus $1.1 million a year earlier, and a $17.5 million quarterly net loss. - The agreement had a 12-month pause; Novo gave notice on November 3. - Cash of $124.8 million is expected to fund operations into the second half of 2028. The biotech sector was higher, so sector weakness does not explain the decline.